How Long Does Suboxone Stay in Your System?

Suboxone stays in your system for approximately 7 to 10 days after the last dose.

Buprenorphine, the primary active ingredient in Suboxone, has a half-life of 24 to 42 hours, meaning your body requires 5 to 9 days to fully eliminate the drug from the bloodstream.

Detection windows vary by test type. Urine tests detect Suboxone for 7 to 14 days, blood tests for 1 to 3 days, saliva tests for 2 to 5 days, and hair follicle tests for up to 90 days.

Whether you are transitioning between medications or preparing for a drug screening, knowing how your body processes Suboxone helps you plan with your treatment provider.

Key Takeaways

• According to the FDA, Suboxone is an FDA-approved combination medication containing buprenorphine (a partial mu-opioid receptor agonist) and naloxone (an opioid antagonist), prescribed specifically for the treatment of opioid use disorder.
• Buprenorphine’s elimination half-life of 24 to 42 hours makes it one of the longest-acting opioid medications, requiring 5 to 9 days for complete clearance from the body.
• Standard urine drug panels do not routinely detect buprenorphine because it does not metabolize into morphine. A specialized immunoassay panel for buprenorphine and its metabolite norbuprenorphine is required.
• SAMHSA reports that medication-assisted treatment (MAT) with buprenorphine-based medications reduces opioid overdose mortality by approximately 50% and significantly improves treatment retention rates.
• Norbuprenorphine, the primary metabolite of buprenorphine, can remain detectable in urine for up to 14 days in chronic users even after the parent drug has been eliminated.

What Is Suboxone?

Suboxone is a prescription combination medication containing two active ingredients that work together to treat opioid use disorder.

Buprenorphine: Partial Mu-Opioid Receptor Agonist

Buprenorphine is a partial agonist at the mu-opioid receptor, meaning it activates the receptor enough to reduce cravings and prevent withdrawal symptoms without producing the full euphoric effects of full agonist opioids like heroin or oxycodone. This ceiling effect on respiratory depression makes buprenorphine significantly safer than full opioid agonists at therapeutic doses.

Buprenorphine also has high binding affinity for the mu-opioid receptor, which means it effectively blocks other opioids from attaching to and activating the receptor. This pharmacological property reduces the reinforcing effects of opioid use during treatment.

Naloxone: Opioid Antagonist Component

Naloxone is an opioid antagonist included in Suboxone to deter misuse by injection. When Suboxone is taken sublingually (under the tongue) as prescribed, naloxone has minimal bioavailability and produces negligible clinical effects.

If someone attempts to dissolve and inject Suboxone, naloxone becomes fully bioavailable and triggers precipitated withdrawal, producing immediate and severe opioid withdrawal symptoms. This abuse-deterrent mechanism is a key reason buprenorphine/naloxone combination products are preferred over buprenorphine-only formulations for most patients.

Forms of Suboxone

Suboxone is available in two primary formulations, each with slightly different pharmacokinetic profiles. Common Suboxone formulations include:

• Sublingual film (strips): Thin dissolving strips placed under the tongue, available in 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg buprenorphine/naloxone doses.
• Sublingual tablets: Dissolvable tablets placed under the tongue, available in the same dose strengths as the film formulation.

How the Body Metabolizes Suboxone

The liver processes buprenorphine through hepatic metabolism primarily mediated by the cytochrome P450 enzyme CYP3A4, with secondary contributions from CYP2C8.

Buprenorphine Metabolism and Half-Life

CYP3A4 converts buprenorphine into norbuprenorphine, an active metabolite that retains partial opioid agonist properties. Norbuprenorphine undergoes further conjugation (glucuronidation) before excretion through both urine and feces.

Buprenorphine’s elimination half-life ranges from 24 to 42 hours, with an average of approximately 37 hours. Complete elimination from the bloodstream requires four to five half-lives, totaling approximately 5 to 9 days depending on individual metabolic factors.

Naloxone Metabolism and Clearance

Naloxone has a significantly shorter half-life of 2 to 12 hours. The liver rapidly metabolizes naloxone through glucuronidation, and the body eliminates it entirely within 1 to 2 days after the last Suboxone dose.

Because buprenorphine persists in the body far longer than naloxone, drug detection discussions about Suboxone focus primarily on buprenorphine and norbuprenorphine detection windows.

Factors That Affect How Long Suboxone Stays in Your System

Individual physiological variables influence how quickly buprenorphine clears from the body. Key factors that extend or shorten Suboxone detection windows include:

• Dosage and duration of use: Higher daily doses and longer treatment durations increase the total amount of buprenorphine and norbuprenorphine stored in body tissues, extending the elimination timeline.
• Liver function and CYP3A4 activity: Individuals with hepatic impairment or reduced CYP3A4 enzyme activity metabolize buprenorphine more slowly, prolonging detection windows.
• Metabolic rate and age: Younger individuals with faster baseline metabolic rates process buprenorphine more efficiently than older adults with age-related declines in hepatic and renal function.
• Body mass and fat composition: Buprenorphine is lipophilic (fat-soluble), meaning it accumulates in adipose tissue and releases slowly back into the bloodstream during elimination.
• Urinary pH: Acidic urine accelerates renal excretion of buprenorphine metabolites, while alkaline urine slows clearance through increased tubular reabsorption.
• Concurrent medications: Drugs that inhibit CYP3A4 (such as ketoconazole and certain HIV protease inhibitors) slow buprenorphine metabolism, while CYP3A4 inducers (such as rifampin) accelerate clearance.

Suboxone Detection Times by Test Type

Suboxone detection windows differ significantly depending on which biological sample is analyzed and whether the test specifically targets buprenorphine.

Urine Testing for Suboxone

Standard opioid urine immunoassays screen for morphine and do not detect buprenorphine because buprenorphine does not metabolize into morphine. A specific buprenorphine/norbuprenorphine immunoassay panel is required to identify Suboxone use in urine.

Buprenorphine becomes detectable in urine within approximately 40 minutes of sublingual administration. For individuals taking therapeutic doses, urine tests typically remain positive for 7 to 10 days after the last dose. Chronic users or those on higher doses may produce positive results for up to 14 days due to norbuprenorphine glucuronide accumulation.

Blood Testing for Suboxone

Blood tests detect buprenorphine for approximately 1 to 3 days after the last dose. Norbuprenorphine and its glucuronide conjugates can remain detectable in blood for up to 150 hours (approximately 6 days) in some individuals.

Blood testing is primarily used in clinical and emergency settings rather than routine drug screening. Peak buprenorphine blood plasma concentration occurs approximately 1 to 2 hours after sublingual administration.

Saliva Testing for Suboxone

Saliva tests detect buprenorphine for 2 to 5 days after the last dose. Because Suboxone is administered sublingually, oral fluid samples collected shortly after dosing may show elevated buprenorphine concentrations from residual drug in the oral cavity rather than from systemic absorption.

Saliva testing is less commonly used for Suboxone detection compared to urine testing. However, it offers a non-invasive collection method that eliminates the privacy concerns associated with observed urine collection.

Hair Follicle Testing for Suboxone

Hair follicle analysis can detect buprenorphine and norbuprenorphine for up to 90 days. As with other drugs, metabolites deposit into the growing hair shaft through the bloodstream, creating a chronological record of substance exposure.

Hair testing for buprenorphine is not widely used in clinical practice due to cost and the limited utility of detecting a legitimately prescribed medication-assisted treatment medication.

Does Suboxone Show Up on a Standard Drug Test?

Suboxone does not appear on standard 5-panel or 12-panel drug tests because these panels screen for morphine-derived opioids, and buprenorphine follows a completely different metabolic pathway.

When Specific Testing Is Required

Employers, courts, and treatment programs that need to confirm or rule out buprenorphine use must order a specific buprenorphine immunoassay or expanded opioid panel. This specialized test targets buprenorphine and its metabolite norbuprenorphine directly.

Individuals prescribed Suboxone for opioid use disorder should inform their testing authority that they are taking a legitimately prescribed medication. Providing documentation from the prescribing physician prevents a positive buprenorphine result from being misinterpreted as illicit drug use.

Cross-Reactivity Considerations

Some immunoassay platforms may produce false-positive results for buprenorphine when other structurally similar compounds are present. Confirmatory testing by gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) definitively identifies buprenorphine and distinguishes it from cross-reacting substances.

Side Effects and Risks of Suboxone

Suboxone is considered safe and effective when prescribed and monitored by a qualified physician, but it produces side effects that patients should understand.

Common Side Effects

Therapeutic doses of Suboxone produce predictable partial opioid agonist effects. Frequently reported common side effects include:

• Headache and dizziness: Partial mu-opioid receptor activation produces mild CNS effects including headache intensity that typically diminishes within the first weeks of treatment.
• Nausea and constipation: Opioid receptor activation in the gastrointestinal tract slows motility and reduces bowel frequency, producing constipation that may require dietary management or stool softeners.
• Insomnia or drowsiness: Some patients experience sleep disruption during Suboxone initiation as the brain adjusts to the transition from full agonist opioids to partial agonist buprenorphine.
• Oral numbness and tongue pain: Sublingual administration can cause localized oral mucosal irritation, particularly with film formulations that dissolve directly against the tongue tissue.

Severe Side Effects

Rare but medically significant adverse effects can occur with Suboxone. Severe side effects that warrant immediate medical evaluation include:

• Respiratory depression: Although buprenorphine has a ceiling effect on respiratory depression at therapeutic doses, combining Suboxone with benzodiazepines, alcohol, or other CNS depressants can overwhelm this protective mechanism.
• Hepatotoxicity: Buprenorphine can cause elevated liver enzymes and hepatic injury, particularly in patients with pre-existing liver disease or concurrent hepatitis C infection.
• Precipitated withdrawal: Taking Suboxone too soon after the last dose of a full opioid agonist (before adequate withdrawal symptoms emerge) triggers rapid and severe precipitated withdrawal driven by buprenorphine’s displacement of the full agonist from opioid receptors.
• Allergic reaction: Anaphylaxis and severe hypersensitivity reactions to Suboxone components, though rare, require emergency medical intervention.

Long-Term Considerations

Long-term Suboxone maintenance therapy is well-supported by clinical evidence as an effective strategy for managing opioid use disorder. Chronic buprenorphine use produces physical dependence, which means gradual dose tapering under medical supervision is necessary to avoid withdrawal symptoms upon discontinuation.

Patients who discontinue Suboxone abruptly after extended maintenance therapy experience opioid withdrawal symptoms including muscle aches, anxiety, insomnia, diarrhea, and cravings. These withdrawal symptoms are generally less severe than withdrawal from full agonist opioids but can persist for 2 to 4 weeks depending on the duration of treatment and taper schedule.

Treatment for Opioid Use Disorder at Carolina Center for Recovery

Carolina Center for Recovery in Charlotte, North Carolina provides individualized treatment for opioid use disorder including medically supervised detoxification and ongoing MAT support.

Medical Detox Program

The medical detox unit provides 24/7 physician-supervised withdrawal management for individuals transitioning off opioids or adjusting medication-assisted treatment protocols. Detox staff initiate individualized buprenorphine induction protocols within the first 24 hours of admission to stabilize withdrawal and reduce cravings.

Residential Treatment Program

The residential treatment program offers structured daily programming with CBT, DBT, individual therapy, group therapy, and holistic modalities. Psychiatric evaluation and medication management begin on the first day, ensuring MAT medications are properly initiated or continued throughout the treatment episode.

Partial Hospitalization and Outpatient Programs

The partial hospitalization program and intensive outpatient program deliver step-down care for clients who have completed residential treatment or need flexible scheduling to maintain work and family responsibilities. Carolina Center for Recovery’s admissions team completes insurance verification and can arrange same-day assessments when bed availability permits.

“Medication-assisted treatment is a core part of our clinical toolkit at Carolina Center for Recovery. Our medical team monitors every patient through hourly nursing rounds and 15-minute behavioral health checks in the first 24 hours, so MAT protocols like Suboxone are adjusted in real time based on how a patient is actually responding.”

— Sahil Talwar, PA-C, MBA, Medical Provider at Carolina Center for Recovery

Frequently Asked Questions

What Is the Washout Period for Suboxone?

The washout period for Suboxone refers to the time required for buprenorphine to clear the body before transitioning to another opioid medication. Buprenorphine’s high receptor binding affinity means it occupies mu-opioid receptors for 24 to 72 hours after the last dose. Most clinicians recommend waiting at least 3 to 5 days after the final Suboxone dose before initiating a full opioid agonist to avoid reduced efficacy.

What Is the 3-Day Suboxone Rule?

The 3-day rule refers to a federal regulation allowing physicians to administer (but not prescribe) buprenorphine for up to 72 hours in emergency situations without requiring a special DEA waiver. This provision enables emergency departments and urgent care settings to provide short-term buprenorphine treatment while connecting patients to ongoing prescription medication management.

How Long Is Suboxone Detectable in Urine?

Buprenorphine is detectable in urine for 7 to 14 days after the last dose, depending on dose, duration of use, and individual metabolism. Standard opioid urine panels do not detect buprenorphine because it does not metabolize into morphine. A specific buprenorphine immunoassay is required, and norbuprenorphine glucuronide may persist in urine longer than the parent drug.

Which Substance Has the Longest Detection Time in Urine?

Among commonly tested substances, cannabis (THC) typically has the longest urine detection window, with chronic heavy users testing positive for 30 days or more due to THC storage in adipose tissue. Buprenorphine (Suboxone) can remain detectable for up to 14 days in chronic users. PCP can also persist for 2 to 4 weeks in heavy users.

Can You Take Suboxone and Still Pass a Drug Test?

Standard 5-panel and 12-panel drug tests do not detect buprenorphine, so individuals taking Suboxone as prescribed will typically pass these routine screenings. However, expanded panels that include a specific buprenorphine assay will identify the medication. Providing proof of a valid Suboxone prescription to the testing authority prevents a positive result from being classified as illicit drug use.

References

1. U.S. Food and Drug Administration. (2023). Suboxone (buprenorphine and naloxone) sublingual film prescribing information. https://www.fda.gov
2. Substance Abuse and Mental Health Services Administration. (2024). Medications for opioid use disorder: Treatment improvement protocol (TIP) 63. https://www.samhsa.gov/medications-substance-use-disorders
3. National Institute on Drug Abuse. (2024). How do medications to treat opioid use disorder work? https://nida.nih.gov/publications/research-reports/medications-to-treat-opioid-addiction
4. Centers for Disease Control and Prevention. (2024). Medication-assisted treatment for opioid use disorder. https://www.cdc.gov
5. American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). American Psychiatric Association Publishing.
6. Moody, D. E., et al. (2009). Urinary detection times and metabolite/parent compound ratios after a single dose of buprenorphine. Journal of Analytical Toxicology, 33(3), 152-159.
7. Substance Abuse and Mental Health Services Administration. (2025). Key substance use and mental health indicators in the United States: Results from the 2024 National Survey on Drug Use and Health. https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/national-releases/2024